Olanzapine is under clinical development by Impel Pharmaceuticals and currently in Phase II for Autism Spectrum Disorder (ASD). According to GlobalData, Phase II drugs for Autism Spectrum Disorder (ASD) have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Olanzapine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olanzapine overview

Olanzapine (INP-105) is under development for the treatment of agitation and aggression in patients with autism spectrum disorder (ASD). The therapeutic candidate is formulated as powder and administered through nasal route. It acts by interfering with the interaction between D1 and D2 dopamine receptor. The therapeutic candidate is delivered through precision olfactory delivery (POD) technology.

Impel Pharmaceuticals overview

Impel Pharmaceuticals (Impel), formerly Impel Neuropharma Inc, is a clinical-stage biotechnology company that develops intranasal drug treatments for central nervous system disorders. The company’s pipeline product portfolio such as Trudhesa (formerly known as INP104), a liquid solution for the treatment of acute migraine; and INP105, olanzapine for the treatment of bipolar disorder. It also develops Precision Olfactory Delivery technology, a nasal drug delivery platform that delivers drugs for improved biodistribution. Impel’s products are used for the treatment of pain, depression, bipolar disorder, Alzheimer’s disease, migraine, and Parkinson’s disease, among others. The company serves pharmaceutical and biotechnology companies, and premier academic research institutions. It has operational Norwest Venture Partners, Vivo Capital, 5Am Ventures and venBio Partners. Impel is headquartered in Seattle, Washington, the US.

For a complete picture of Olanzapine’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.